Interleukin-4 and Interleukin-17 are associated with coronary artery disease.
coronary artery disease
cytokines
high-density lipoprotein cholesterol
interleukin-17
interleukin-4
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
25 Dec 2023
25 Dec 2023
Historique:
revised:
12
10
2023
received:
13
06
2023
accepted:
30
10
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
26
12
2023
Statut:
aheadofprint
Résumé
The present study aimed to examine the correlation between serum cytokine levels and the incidence of coronary artery disease (CAD), a leading cause of mortality globally, which is known to have a strong association with inflammatory factors. The study further sought to determine the predictors of CAD to distinguish patients with coronary artery lesions from those suspected of having CAD. In this study, 487 patients who underwent coronary angiography as a result of suspected CAD but without acute myocardial infarction (AMI) were recruited. The serum levels of the cytokines interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, tumor necrosis factor-α, interferon (IFN)-α, and IFN-γ were measured using a multiplexed particle-based flow cytometric assay technique. The results of the study revealed that the levels of IL-4, IL-12p70, IL-17, IFN-α, and IFN-γ in the CAD group were significantly lower compared to those in the non-CAD group. Multivariate logistic regression analysis indicated that two serum cytokines (IL-4 and IL-17), one protective factor (high-density lipoprotein cholesterol [HDL-C]), and three risk factors (sex, smoking, and diabetes) were independently predictive of CAD. The receiver operating characteristic curve analysis showed that the combined use of these predictors in a multivariate model demonstrated good predictive performance for CAD, as evidenced by an area under the curve value of 0.826. The results of the study indicated that serum IL-4 and IL-17 levels serve as independent predictors of CAD. The risk prediction model established in the research, which integrates these serum cytokines (IL-4 and IL-17) with relevant clinical risk factors (gender, smoking, and diabetes) and the protective factor HDL-C, holds the potential to differentiate patients with CAD from those suspected of having CAD but without AMI.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 82170453
Informations de copyright
© 2023 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
Références
Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016;2016(1):CD001800. doi:10.1002/14651858.CD001800.pub3
Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2013;34(10):719-728. doi:10.1093/eurheartj/ehs411
Ranjit N. Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis. Arch Intern Med. 2007;167(2):174-181. doi:10.1001/archinte.167.2.174
Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315-327. doi:10.1161/CIRCRESAHA.118.313591
Zhu Y, Xian X, Wang Z, et al. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules. 2018;8(3):80. doi:10.3390/biom8030080
Held C, White HD, Stewart RAH, et al. Inflammatory biomarkers Interleukin-6 and C-Reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. J Am Heart Assoc. 2017;6(10):e005077. doi:10.1161/JAHA.116.005077
Ray M, Autieri MV. Regulation of pro- and anti-atherogenic cytokines. Cytokine. 2019;122:154175. doi:10.1016/j.cyto.2017.09.031
Robert M, Miossec P. Effects of interleukin 17 on the cardiovascular system. Autoimmun Rev. 2017;16(9):984-991. doi:10.1016/j.autrev.2017.07.009
Taleb S, Tedgui A. IL-17 in atherosclerosis: the good and the bad. Cardiovasc Res. 2018;114(1):7-9. doi:10.1093/cvr/cvx225
Qamar A, Rader DJ. Effect of interleukin 1β inhibition in cardiovascular disease. Curr Opin Lipidol. 2012;23(6):548-553. doi:10.1097/MOL.0b013e328359b0a6
McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694-702. doi:10.1136/annrheumdis-2013-204345
Haraoui B, Bykerk V. Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2007;3(1):99-105. doi:10.2147/tcrm.2007.3.1.99
Kazimierczyk E, Eljaszewicz A, Zembko P, et al. The relationships among monocyte subsets, miRNAs and inflammatory cytokines in patients with acute myocardial infarction. Pharmacol Rep. 2019;71(1):73-81. doi:10.1016/j.pharep.2018.09.007
Westman PC, Lipinski MJ, Luger D, et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. JACC. 2016;67(17):2050-2060. doi:10.1016/j.jacc.2016.01.073
Phatharajaree W, Phrommintikul A, Chattipakorn N. Matrix metalloproteinases and myocardial infarction. Can J Cardiol. 2007;23(9):727-733. doi:10.1016/s0828-282x(07)70818-8
Liu S, Wang C, Guo J, et al. Serum cytokines predict the severity of coronary artery disease without acute myocardial infarction. Front Cardiovasc Med. 2022;9:896810. doi:10.3389/fcvm.2022.896810
Gencer S, Evans BR, van der Vorst EPC, Döring Y, Weber C. Inflammatory chemokines in atherosclerosis. Cells. 2021;10(2):226. doi:10.3390/cells10020226
Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278(5):483-493. doi:10.1111/joim.12406
Smith E, Prasad KMR, Butcher M, et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2010;121(15):1746-1755. doi:10.1161/CIRCULATIONAHA.109.924886
Gisterå A, Robertson AKL, Andersson J, et al. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med. 2013;5(196):196ra100. doi:10.1126/scitranslmed.3006133
Butcher MJ, Gjurich BN, Phillips T, Galkina EV. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res. 2012;110(5):675-687. doi:10.1161/CIRCRESAHA.111.261784
Gao Q, Jiang Y, Ma T, et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol. 2010;185(10):5820-5827. doi:10.4049/jimmunol.1000116
Erbel C, Chen L, Bea F, et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol. 2009;183(12):8167-8175. doi:10.4049/jimmunol.0901126
Butcher MJ, Waseem TC, Galkina EV. Smooth muscle cell-derived interleukin-17C plays an atherogenic role via the recruitment of proinflammatory Interleukin-17A+ T cells to the aorta. Arterioscler Thromb Vasc Biol. 2016;36(8):1496-1506. doi:10.1161/ATVBAHA.116.307892
Engelbertsen D, Andersson L, Ljungcrantz I, et al. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. Arterioscler Thromb Vasc Biol. 2013;33(3):637-644. doi:10.1161/ATVBAHA.112.300871
Engelbertsen D, Rattik S, Knutsson A, Björkbacka H, Bengtsson E, Nilsson J. Induction of T helper 2 responses against human apolipoprotein B100 does not affect atherosclerosis in ApoE−/− mice. Cardiovasc Res. 2014;103(2):304-312. doi:10.1093/cvr/cvu131
King VL, Cassis LA, Daugherty A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am J Pathol. 2007;171(6):2040-2047. doi:10.2353/ajpath.2007.060857
Mirhafez SR, Zarifian A, Ebrahimi M, et al. Relationship between serum cytokine and growth factor concentrations and coronary artery disease. Clin Biochem. 2015;48(9):575-580. doi:10.1016/j.clinbiochem.2015.02.002
Walch L, Massade L, Dufilho M, Brunet A, Rendu F. Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis. 2006;187(2):285-291. doi:10.1016/j.atherosclerosis.2005.09.016
Lee YW, Kühn H, Hennig B, Neish AS, Toborek M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol. 2001;33(1):83-94. doi:10.1006/jmcc.2000.1278
Cornicelli JA, Butteiger D, Rateri DL, Welch K, Daugherty A. Interleukin-4 augments acetylated LDL-induced cholesterol esterification in macrophages. J Lipid Res. 2000;41(3):376-383.
Martins TB, Anderson JL, Muhlestein JB, et al. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Path. 2006;125(6):906-913. doi:10.1309/Q3E6-KF0Q-D3U3-YL6T
Boekholdt SM, Peters RJG, Hack CE, et al. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2004;24(8):1503-1508. doi:10.1161/01.ATV.0000134294.54422.2e
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. The Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100(3):230-235. doi:10.1161/01.cir.100.3.230
Ye J, Wang Y, Wang Z, et al. Roles and mechanisms of Interleukin-12 family members in cardiovascular diseases: opportunities and challenges. Front Pharmacol. 2020;11:129. doi:10.3389/fphar.2020.00129
van der Heijden T, Bot I, Kuiper J. The IL-12 cytokine family in cardiovascular diseases. Cytokine. 2019;122:154188. doi:10.1016/j.cyto.2017.10.010
Zhou RH, Shi Q, Gao HQ, Shen BJ. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J Atheroscler Thromb. 2001;8(1):30-32. doi:10.5551/jat1994.8.30
Pasqui AL, Di Renzo M, Bova G, et al. Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes. Clin Exp Med. 2006;6(1):38-44. doi:10.1007/s10238-006-0092-9
Niessner A, Shin MS, Pryshchep O, Goronzy J, Chaikof EL, Weyand CM. Synergistic proinflammatory effects of the antiviral cytokine Interferon-α and Toll-Like receptor 4 ligands in the atherosclerotic plaque. Circulation. 2007;116(18):2043-2052. doi:10.1161/CIRCULATIONAHA.107.697789
Rusnak J, Fastner C, Behnes M, Mashayekhi K, Borggrefe M, Akin I. Biomarkers in stable coronary artery disease. Curr Pharm Biotechnol. 2017;18(6):456-471. doi:10.2174/1389201018666170630120805